Hereditary Angioedema Therapeutics Market to Grow with a CAGR of 7.23% through 2028
Growing emphasis on personalized medicine approaches are
expected to drive the Global Hereditary Angioedema Therapeutics Market growth
in the forecast period, 2024-2028.
According to TechSci Research report, “Hereditary
Angioedema Therapeutics Market – Global Industry Size, Share,
Trends, Competition Forecast & Opportunities, 2028”, the Global Hereditary
Angioedema Therapeutics Market stood at USD 3.12 billion in 2022 and is
anticipated to grow with a CAGR of 7.23% in the forecast period, 2024-2028. he
Global Hereditary Angioedema Therapeutics Market is characterized by ongoing
research, innovative drug development, and increased patient awareness. As the
understanding of HAE continues to expand and more effective treatments become
available, this market is expected to grow steadily, offering hope and improved
quality of life for individuals affected by this rare and debilitating genetic
disorder. One of the primary drivers propelling the HAE therapeutics market is
the continuous advancement in research and development efforts. Pharmaceutical
and biotechnology companies are investing heavily in understanding the
underlying mechanisms of HAE and developing innovative therapies. These R&D
initiatives have led to the discovery of novel treatment options, including
monoclonal antibodies that target specific proteins involved in HAE
pathogenesis. These therapies have proven highly effective in preventing and
managing HAE attacks, significantly improving patients' quality of life. Monoclonal antibodies have emerged as a game-changer
in the treatment of Hereditary Angioedema. Drugs like Lanadelumab and Ecallantide,
which specifically target the activity of C1 esterase inhibitor (C1-INH), have
revolutionized the treatment landscape. These medications offer a more
convenient and efficient way to prevent HAE attacks, reducing the frequency and
severity of symptoms. The introduction of these monoclonal antibodies has
reshaped treatment protocols and garnered significant attention from healthcare
providers and patients alike. Another crucial factor driving the HAE therapeutics
market is the rising awareness of Hereditary Angioedema. Improved education and
awareness campaigns have helped healthcare professionals recognize the disease
more accurately, leading to earlier diagnoses. As a result, more patients are
now being identified and receiving appropriate treatment, thereby expanding the
patient pool and increasing the demand for HAE therapies.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Hereditary Angioedema Therapeutics Market.”
The HAE therapeutics market has witnessed a global
expansion of treatment options, benefiting patients in different regions.
Previously, access to advanced therapies was limited in many parts of the
world, but efforts to expand market reach have led to increased availability
and affordability. This globalization of treatment options is expected to drive
market growth further. The Global Hereditary Angioedema Therapeutics Market
is segmented into Treatment, End User, Virus, Regional Distribution, And Company. Based on the Drug Class, C1 Esterase
Inhibitor (C1-INH) is anticipated to be the fastest growing segment in the
global market for Global Hereditary Angioedema Therapeutics Market in 2022. This
is attributed to its potential to effectively target the bradykinin pathway,
which plays a pivotal role in HAE pathogenesis, thereby offering a promising
and specialized treatment approach for this rare genetic disorder.
Based on the Distribution Channel, the Retail Pharmacy
segment emerged as the dominant player in the global market for Global
Hereditary Angioedema Therapeutics Market in 2022. Retail pharmacies are widely
accessible to the general population. They are found in local communities and
neighborhoods, making it convenient for patients to access their prescribed
medications without having to travel long distances or visit specialized
medical facilities. Retail pharmacies offer a convenient and familiar
environment for patients to pick up their HAE medications. Patients can combine
their regular visits to the pharmacy with other shopping or errands, saving
them time and effort. Retail pharmacies typically stock a wide range of
medications, including prescription drugs for various conditions. This variety
ensures that HAE patients can readily access their prescribed therapies, contributing
to higher demand for HAE therapeutics through this channel. Retail pharmacists are trained to dispense
prescription medications and provide counseling to patients on proper
medication usage. They play a crucial role in ensuring that HAE patients receive
the right medications and understand how to use them effectively.
Based on the Application, the Prophylaxis segment
emerged as the dominant player in the global market for Global Hereditary
Angioedema Therapeutics Market in 2022. Prophylactic treatment aims to prevent
HAE attacks before they occur. This approach provides patients with a higher
level of control over their condition, as it reduces the likelihood of
experiencing painful and potentially life-threatening swelling episodes. Prophylactic
treatment can significantly improve the quality of life for individuals with
HAE. By reducing the frequency and severity of attacks, patients can lead more
predictable and less stressful lives, free from the constant fear of sudden
attacks. Prophylaxis is particularly crucial for patients with severe forms of
HAE who are at a higher risk of experiencing frequent and severe attacks. By
using prophylactic medications, these patients can minimize their exposure to
attack triggers and lower their risk of complications.
North America emerged as the dominant player in the
global Hereditary Angioedema Therapeutics Market in 2022, holding the largest
market share. North America often has early access to cutting-edge HAE
therapies due to the presence of major pharmaceutical companies and clinical
research centers. This allows patients to benefit from the latest advancements
in HAE treatment options, including monoclonal antibodies and other innovative
therapies. North America has a
relatively higher prevalence of HAE compared to other regions. This increased
disease burden contributes to a larger patient population seeking treatment,
which, in turn, drives the demand for HAE therapeutics. The region boasts a well-developed and advanced
healthcare infrastructure, including a network of specialized treatment
centers, hospitals, and clinics. This infrastructure facilitates the diagnosis,
treatment, and management of HAE, making it easier for patients to access care
and therapies.
Major companies operating in Global Hereditary
Angioedema Therapeutics Market are:
- Shire plc
- Sanofi SA
- Pharming Healthcare Inc.
- Attune Pharmaceuticals
- Adverum Biotechnologies
- Arrowhead Pharmaceuticals
- Ionis Pharmaceuticals
- BioCryst Pharmaceuticals Inc.
- CSL Behring.
- CENTOGENE N.V
Download Free Sample Report
Customers can also request for 10%
free customization on this report.
“The Global
Hereditary Angioedema (HAE) Therapeutics Market is poised for significant
growth in the coming years. Increased disease awareness among healthcare
providers and the public is leading to earlier diagnosis and treatment,
expanding the patient pool in need of HAE therapeutics. The emergence of
innovative treatment options, such as monoclonal antibodies and personalized
medicine approaches, is revolutionizing HAE management, improving patient
outcomes, and driving demand for these advanced therapies. Additionally,
pharmaceutical companies continue to invest in research and development,
leading to the development of more effective and accessible HAE treatments.
Lastly, a growing emphasis on patient-centric care and a global push for
improved healthcare infrastructure are expected to further boost the market.” said
Mr. Karan Chechi, Research Director with TechSci Research, a research-based
management consulting firm.
“Hereditary Angioedema Therapeutics Market -
Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028
Segmented By Drug Class (C1 Esterase Inhibitor, Selective Bradykinin B2
Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes), By Distribution
Channel (Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels), By
Application (Prophylaxis, On-demand) By Region and Competition”, has evaluated
the future growth potential of Global Hereditary Angioedema Therapeutics Market
and provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Hereditary Angioedema Therapeutics Market.
Contact
Techsci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +13322586602
Email: [email protected]
Website: www.techsciresearch.com